Drug-related AEs grade ≥3
| AE . | Dose (mg/m2 per day) . | N (%) . |
|---|---|---|
| Patients with ≥1 drug-related TEAE ≥ grade 3 | All | 9 (18) |
| Leukocytosis | 36, 80, 90 | 3 (6) |
| Cardiac failure congestive | 90 | 2 (4) |
| Cardiac failure | 90 | 1 (2) |
| Ejection fraction decreased* | 90 | 1 (2) |
| Cardiorespiratory arrest* | 90 | 1 (2) |
| Liver function test abnormal† | 54 | 1 (2) |
| White blood cell count increased | 54 | 1 (2) |
| Anemia | 54 | 1 (2) |
| Electrocardiogram QT prolonged | 54 | 1 (2) |
| Hypophosphatemia | 90 | 1 (2) |
| AE . | Dose (mg/m2 per day) . | N (%) . |
|---|---|---|
| Patients with ≥1 drug-related TEAE ≥ grade 3 | All | 9 (18) |
| Leukocytosis | 36, 80, 90 | 3 (6) |
| Cardiac failure congestive | 90 | 2 (4) |
| Cardiac failure | 90 | 1 (2) |
| Ejection fraction decreased* | 90 | 1 (2) |
| Cardiorespiratory arrest* | 90 | 1 (2) |
| Liver function test abnormal† | 54 | 1 (2) |
| White blood cell count increased | 54 | 1 (2) |
| Anemia | 54 | 1 (2) |
| Electrocardiogram QT prolonged | 54 | 1 (2) |
| Hypophosphatemia | 90 | 1 (2) |